MX2019009724A - Nueva estrategia de inmunoterapia dirigida al vegfr-2. - Google Patents

Nueva estrategia de inmunoterapia dirigida al vegfr-2.

Info

Publication number
MX2019009724A
MX2019009724A MX2019009724A MX2019009724A MX2019009724A MX 2019009724 A MX2019009724 A MX 2019009724A MX 2019009724 A MX2019009724 A MX 2019009724A MX 2019009724 A MX2019009724 A MX 2019009724A MX 2019009724 A MX2019009724 A MX 2019009724A
Authority
MX
Mexico
Prior art keywords
cancer
protein receptor
vegf
copy
dna molecule
Prior art date
Application number
MX2019009724A
Other languages
English (en)
Spanish (es)
Inventor
Lubenau Heinz
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of MX2019009724A publication Critical patent/MX2019009724A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/423—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2019009724A 2017-02-17 2018-02-16 Nueva estrategia de inmunoterapia dirigida al vegfr-2. MX2019009724A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17156718 2017-02-17
PCT/EP2018/053918 WO2018149982A1 (en) 2017-02-17 2018-02-16 Novel vegfr-2 targeting immunotherapy approach

Publications (1)

Publication Number Publication Date
MX2019009724A true MX2019009724A (es) 2019-10-07

Family

ID=58094260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009724A MX2019009724A (es) 2017-02-17 2018-02-16 Nueva estrategia de inmunoterapia dirigida al vegfr-2.

Country Status (13)

Country Link
US (1) US10980868B2 (enExample)
EP (1) EP3583200A1 (enExample)
JP (2) JP7712060B2 (enExample)
KR (2) KR20190117603A (enExample)
CN (1) CN110291187A (enExample)
AU (1) AU2018222777B9 (enExample)
BR (1) BR112019016925A2 (enExample)
CA (1) CA3050833A1 (enExample)
IL (1) IL268186A (enExample)
MX (1) MX2019009724A (enExample)
RU (1) RU2019125436A (enExample)
SG (1) SG11201907391SA (enExample)
WO (1) WO2018149982A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018101722A (ru) * 2015-06-18 2019-07-18 Факсимм Аг Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
JP7598315B2 (ja) * 2018-09-05 2024-12-11 エンエーセー オンコイミュニティ アクスイェ セルスカプ 併用療法用ｄｎａワクチンを標的とするネオアンチゲン
US20230121528A1 (en) * 2020-01-13 2023-04-20 Vaximm Ag Salmonella-based dna vaccines in combination with an antibiotic
CN113527509B (zh) * 2020-04-17 2023-09-26 深圳华大生命科学研究院 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
CA2853656C (en) * 2011-12-22 2020-12-29 Vaximm Ag Method of producing high yield attenuated salmonella strains
JP6325534B2 (ja) 2012-07-05 2018-05-16 バクシム アクチェンゲゼルシャフト 膵臓癌患者用ｄｎａワクチン
MX364922B (es) * 2013-04-25 2019-05-14 Vaximm Ag Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
SI3082850T1 (sl) * 2013-12-18 2020-01-31 Vaximm Gmbh DNA cepivo, ki cilja MSLN za imunoterapijo raka
WO2015142875A1 (en) * 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compositions and methods using modified salmonella
RU2018101722A (ru) * 2015-06-18 2019-07-18 Факсимм Аг Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии
SG11201811258UA (en) 2016-07-13 2019-01-30 Vaximm Ag Process for the production of a dna vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
BR112019016925A2 (pt) 2020-05-26
JP7712060B2 (ja) 2025-07-23
AU2018222777A1 (en) 2019-08-08
IL268186A (en) 2019-09-26
WO2018149982A1 (en) 2018-08-23
AU2018222777B9 (en) 2024-02-22
CA3050833A1 (en) 2018-08-23
US10980868B2 (en) 2021-04-20
KR20240170928A (ko) 2024-12-05
AU2018222777B2 (en) 2024-02-01
CN110291187A (zh) 2019-09-27
RU2019125436A (ru) 2021-03-17
SG11201907391SA (en) 2019-09-27
US20200038496A1 (en) 2020-02-06
JP2023160838A (ja) 2023-11-02
KR20190117603A (ko) 2019-10-16
JP2020507332A (ja) 2020-03-12
EP3583200A1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
Guiu et al. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?
Wang et al. Protein mislocalization: mechanisms, functions and clinical applications in cancer
MX2019008503A (es) Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
CY1124006T1 (el) Συζευγμενα αντισωματα κατα toy ly75 για τη θεραπεια του καρκινου
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
MX2025015210A (es) Receptores de antigeno quimericos dirigidos a cd70
AR097584A1 (es) Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
MX2019009724A (es) Nueva estrategia de inmunoterapia dirigida al vegfr-2.
BR112019001922A2 (pt) receptores de célula t e imunoterapia usando os mesmos
UY36289A (es) ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN
HK1250918A1 (zh) 用於胶质母细胞瘤的egfr导向的car疗法
MX2020012573A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
WO2012054084A3 (en) Antibodies
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
MX380358B (es) Anticuerpo igf-1r y su uso como un vehiculo con especificidad de objetivo para el tratamiento contra el cancer.
MX364922B (es) Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer.
EP2582727A4 (en) ANTIBODIES TO ENDOPLASMINE AND ITS USE
MX2013011354A (es) Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
CY1119351T1 (el) Αντισωματα σε adp-ριβοζυλ κυκλαση 2
MX2019011026A (es) Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer.
BR112016011435A2 (pt) anticorpos anti-matriptase para o tratamento de câncer
PH12016502297A1 (en) Ang2 antibodies
Kocáková et al. Long term experience of patients with unresectable or metastatic KIT positive gastrointestinal stromal tumours.
AR097996A1 (es) Anticuerpos